Sugi Predict

Sugi Predict / Compounds / SCHEMBL382745

SCHEMBL382745

SCHEMBL382745

CC1(C)OB(c2cccc(-n3cccn3)c2)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 6/20 0.42
▸ LIPG Q9Y5X9 6/20 0.42
▸ IRAK4 Q9NWZ3 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ NOTUM Q6P988 1/20 0.38
▸ ERCC1 P07992 1/20 0.37
▸ ERCC4 Q92889 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ PDK2 Q15119 1/20 0.35
▸ TNIK Q9UKE5 1/20 0.35
▸ KAT6A Q92794 1/20 0.34
▸ KCNH2 Q12809 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ FFAR1 O14842 1/20 0.33
▸ GRM5 P41594 1/20 0.33
▸ MPO P05164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2016964 0.84 NOTUM (0.49) LPLLIPGNOTUMKDM4EALDH1A1
SCHEMBL27096635 0.82 KDM4E (0.38) LPLLIPGIRAK4LMNANOTUM
SCHEMBL14822109 0.82 NOTUM (0.51) LPLLIPGIRAK4NOTUM
SCHEMBL30884952 0.82 KDM4E (0.38) LPLLIPGIRAK4LMNANOTUM
SCHEMBL14810685 0.81 IRAK4 (0.45) LPLLIPGIRAK4FFAR1
SCHEMBL23712838 0.81 TDO2 (0.33) LPLLIPGIRAK4LMNANOTUM
SCHEMBL30345421 0.81 TDO2 (0.33) LPLLIPGIRAK4LMNANOTUM
SCHEMBL16322408 0.80 LIPG (0.55) LPLLIPGNOTUMKDM4EALDH1A1
SCHEMBL19435145 0.79 CYP2A6 (0.45) LPLLIPGIRAK4KDM4EALDH1A1
SCHEMBL22040425 0.79 IRAK4 (0.42) LPLLIPGIRAK4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 — — US disclosed
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-06-19 — — US disclosed
US-20250145642-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. 2025-05-08 — — US disclosed
EP-4444317-A2 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
EP-4444312-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
EP-4444309-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 — — EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 — — US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 — — US disclosed
WO-2012059232-A1 CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF PHILIP MORRIS PRODUCTS S.A (CH) 2012-05-10 — — WO disclosed
EP-2408772-A1 COMPOUNDS Medical Research Council Technology (GB) 2012-01-25 — — EP disclosed
WO-2011103546-A1 TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-08-25 — — WO disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 — — US disclosed
WO-2011070987-A1 NOVEL IRIDIUM COMPLEX, ORGANIC LIGHT-EMITTING DEVICE, AND IMAGE DISPLAY APPARATUS CANON KABUSHIKI KAISHA (JP) 2011-06-16 — — WO disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 — — US disclosed
WO-2010106333-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-09-23 — — WO disclosed
US-20100120761-A1 Bicyclic Heterocyclic Compounds as FGFR Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2010-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 LPL 239/4885LIPG 591/4885IRAK4 4439/4885
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP LPL 2/4885LIPG 23/4885IRAK4 4249/4885
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE TDP1, TYMP, TARDBP LPL 2407/4885LIPG 3667/4885IRAK4 3677/4885
US-20100120761-A1 Bicyclic Heterocyclic Compounds as FGFR Inhibitors FGFR3, FGFR1, FGFR2 LPL 4061/4885LIPG 2618/4885IRAK4 816/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP LPL 2/4885LIPG 23/4885IRAK4 4245/4885
US-20100317646-A1 COMPOUNDS CBR3, CNR1, HCAR3 LPL 3016/4885LIPG 4152/4885IRAK4 3764/4885
US-20250145642-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE TARDBP, TDP2, PSEN2 LPL 2029/4885LIPG 2050/4885IRAK4 3658/4885
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE LPL 2723/4885LIPG 3913/4885IRAK4 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.